# EDGAR Filing Document

**Accession Number:** 0001094038
**File Stem:** 0001104659-23-007019
**Filing Date:** 2023-1
**Character Count:** 13839
**Document Hash:** 7ebde4fc679533172206b8e59e4a3908
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-007019.hdr.sgml**: 20230126

**ACCESSION NUMBER**: 0001104659-23-007019

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230126

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230126

**DATE AS OF CHANGE**: 20230126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Marker Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001094038
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 880277072
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37939
- **FILM NUMBER:** 23557914

**BUSINESS ADDRESS:**
- **STREET 1:** 4551 KENNEDY COMMERCE DR.
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77032
- **BUSINESS PHONE:** (713) 400-6400

**MAIL ADDRESS:**
- **STREET 1:** 4551 KENNEDY COMMERCE DR.
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77032

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC.
- **DATE OF NAME CHANGE:** 20170629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TAPIMMUNE INC
- **DATE OF NAME CHANGE:** 20070628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENEMAX CORP
- **DATE OF NAME CHANGE:** 20020718

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**<u>FORM 8-K</u>**

**<u>CURRENT REPORT</u>**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**<u>January 26, 2023</u>**

Date of Report (Date of earliest event reported)

**<u>MARKER THERAPEUTICS, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>001-37939</u>** | **<u>45-4497941</u>** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **4551 Kennedy Commerce Dr.**<br>**<u>Houston, Texas</u>** | **<u>77027</u>** |
| (Address of principal executive offices) | (Zip Code) |

---

**(713) 400-6400**

Registrant's telephone number, including area code

**<u>N/A</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | MRKR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.03** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year** **.** |

---

*(a) Amendment of Amended and Restated Certificate of Incorporation to Effect Reverse Stock Split and Shares Reduction*

On January 26, 2023, Marker Therapeutics, Inc. (the "***Company***") filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "***Amendment***") with the Secretary of State of the State of Delaware to effect a one-for-ten (1-for-10) reverse stock split (the "***Reverse Stock Split***") of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000 (the "***Shares Reduction***"). The Amendment will be effective at 5:00 p.m. Eastern Time on January 26, 2023. A series of alternate amendments to effect (i) a reverse stock split and (ii) a reduction in the total number of authorized shares of the Company's common stock was approved by the Company's stockholders at the Company's 2022 Annual Meeting of Stockholders held on May 24, 2022, and the specific one-for-ten (1-for-10) Reverse Stock Split and corresponding Shares Reduction was subsequently approved by the Company's board of directors on January 24, 2023.

The Amendment provides that, at the effective time of the Amendment, every ten (10) shares of the Company's issued and outstanding common stock will automatically be combined into one issued and outstanding share of common stock and the authorized shares of the Company's common stock will reduce from 300,000,000 to 30,000,000, without any change in par value per share. The Reverse Stock Split will affect all shares of the Company's common stock outstanding immediately prior to the effective time of the Amendment. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and warrants issued by the Company and outstanding immediately prior to the effective time of the Amendment, which will result in a proportionate decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options and warrants and a proportionate increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective time of the Amendment will be reduced proportionately.

No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof. The Reverse Stock Split will affect all stockholders proportionately and will not affect any stockholder's percentage ownership of the Company's common stock (except to the extent that the Reverse Stock Split results in any stockholder owning only a fractional share).

The Company's common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on Thursday, January 27, 2023. The new CUSIP number for the Company's common stock following the Reverse Stock Split is 57055L 206.

The foregoing description is qualified in its entirety by the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| [3.1](tm234466d1_ex3-1.htm) | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of Marker Therapeutics, Inc., effective January 26, 2023](tm234466d1_ex3-1.htm) |
| 104 | Inline XBRL for the cover page of this Current Report on Form 8-K |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Marker Therapeutics, Inc.** | **Marker Therapeutics, Inc.** |
| Dated: January 26, 2023 | By: | /s/ Peter Hoang |
|  |  | Peter Hoang |
|  |  | *President and Chief Executive Officer* |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT<br> TO<br> AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br> OF<br> MARKER THERAPEUTICS, INC.**

Marker Therapeutics, Inc. (the "***Company***"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "***DGCL***"), does hereby certify that:

**FIRST:** The name of this corporation is Marker Therapeutics, Inc., and the date on which the Certificate of Incorporation of this corporation was originally filed with the Secretary of State of the State of Delaware was October 17, 2018, under the original name Marker Therapeutics, Inc., and was amended on May 24, 2022.

**SECOND:** The Board of Directors of the Company (the "***Board***"), acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions amending its Certificate of Incorporation (the "***Certificate of Incorporation***"), as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Effective as of the effective time of 5:00 p.m., Eastern Time, on January 26, 2023 (the "  ***Effective Time*** "), each ten (10) shares of the Company's Common Stock, par value $0.001 per share, issued and outstanding
immediately prior to the Effective Time shall, automatically and without any action on the part of the Company or the respective holders
thereof, be combined into one (1) share of Common Stock without increasing or decreasing the par value of each share of Common Stock
(the "  ***Reverse Split*** "); provided, however, no fractional shares of Common Stock shall be issued as a result of
the Reverse Split and, in lieu thereof, upon receipt after the Effective Time by the exchange agent selected by the Company of a properly
completed and duly executed transmittal letter and, where shares are held in certificated form, the surrender of the stock certificate(s) formerly
representing shares of pre-Reverse Split Common Stock, any stockholder who would otherwise be entitled to a fractional share of post-Reverse
Split Common Stock as a result of the Reverse Split, following the Effective Time (after taking into account all fractional shares of
post-Reverse Split Common Stock otherwise issuable to such stockholder), shall be entitled to receive a cash payment (without interest)
equal to the fractional share of post-Reverse Split Common Stock to which such stockholder would otherwise be entitled multiplied by the
average of the closing sales prices of a share of the Company's Common Stock (as adjusted to give effect to the Reverse Split) on
The Nasdaq Stock Market for each of the five (5) consecutive trading days immediately preceding the date this Certificate of Amendment
is filed with the Secretary of State of the State of Delaware. Each stock certificate that, immediately prior to the Effective Time, represented
shares of pre-Reverse Split Common Stock shall, from and after the Effective Time, automatically and without any action on the part of
the Company or the respective holders thereof, represent that number of whole shares of post-Reverse Split Common Stock into which the
shares of pre-Reverse Split Common Stock represented by such certificate shall have been combined (as well as the right to receive cash
in lieu of any fractional shares of post-Reverse Split Common Stock as set forth above); provided, however, that each holder of record
of a certificate that represented shares of pre-Reverse Split Common Stock shall receive, upon surrender of such certificate, a new certificate
representing the number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common Stock represented
by such certificate shall have been combined pursuant to the Reverse Split, as well as any cash in lieu of fractional shares of post-Reverse
Split Common Stock to which such holder may be entitled as set forth above. The Reverse Split shall be effected on a record holder-by-record
holder basis, such that any fractional shares of post-Reverse Split Common Stock resulting from the Reverse Split and held by a single
record holder shall be aggregated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Section A of Article IV of the Certificate of Incorporation is amended and restated to read
in its entirety as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares which the Corporation is authorized to issue is 35,000,000 shares, consisting of (i) 30,000,000 shares of Common Stock, $0.001 par value per share, and (ii) 5,000,000 shares of Preferred Stock, $0.001 par value per share."

**THIRD:** The foregoing amendment to the Certificate of Incorporation was duly approved by the Board.

**FOURTH**: Thereafter, pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the DGCL.

**FIFTH**: This amendment to the Certificate of Incorporation shall be effective on and as of as of the effective time of 5:00 p.m., Eastern Time, on January 26, 2023.

**[SIGNATURE PAGE FOLLOWS]**

**IN WITNESS WHEREOF,** Marker Therapeutics, Inc. has caused this Certificate of Amendment to be executed by its President, Chief Executive Officer as of January 26, 2023.

---

| | |
|:---|:---|
| By: | /s/ Peter Hoang |
|  | Peter Hoang |
|  | President, Chief Executive Officer |

---